16 Results for "

P-glycoprotein transporter

" in MedChemExpress (MCE) Product Catalog:
Products (16)

16 Results for "P-glycoprotein transporter" in MCE Product Catalog:

31
31 Publications Verification
Cat. No.: HY-50879
CAS No.: 143664-11-3
Synonyms: GF120918; GW0918; GG918; GW120918
Target:  

P-glycoprotein BCRP

Research Areas:  

Cancer

Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer .
loading...
    loading...
31
31 Publications Verification
Cat. No.: HY-50880
CAS No.: 143851-98-3
Synonyms: GF120918A
Target:  

P-glycoprotein BCRP

Research Areas:  

Cancer

Elacridar hydrochloride (GF120918A) is an orally active P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar hydrochloride can be used to examine the influence of efflux transporters on agent distribution to brain and it can be used for the research of cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0387
CAS No.: 122647-32-9
Synonyms: U70226E
Target:  

Potassium Channel

Research Areas:  

Cardiovascular Disease

Ibutilide (U70226E) fumarate, an action potential-prolonging antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K + current (IKr) in AT-1 cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0387A
CAS No.: 122647-31-8
Synonyms: U70226E free base
Target:  

Potassium Channel

Research Areas:  

Cardiovascular Disease

Ibutilide (U70226E free base), an action potential-prolonging antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K + current (IKr) in AT-1 cells .
loading...
    loading...
Cat. No.: HY-132189
CAS No.: 197509-46-9
Target:  

P-glycoprotein

Research Areas:  

Neurological Disease

Laniquidar is a non-competitive P-gp inhibitor with an IC50 of 0.51 μM. Laniquidar binds to the P-gp transporter with high affinity and exhibits low activity as a substrate. Laniquidar is applicable to epilepsy-related research .
loading...
    loading...
Cat. No.: HY-126940
CAS No.: 19912-61-9
Purity:  99.83%
Furanodiene is a natural terpenoid isolated from Rhizoma Curcumae. Furanodiene plays anti-cancer effects through anti-angiogenesis and inducing ROS production, DNA strand breaks and apoptosis. Furanodiene suppresseed efflux transporter Pgp (P-glycoprotein) function and reduced Pgp protein level .
loading...
    loading...
Cat. No.: HY-113805
CAS No.: 1031367-64-2
Purity:  99.50%
Target:  

P-glycoprotein

Research Areas:  

Cancer

MC70 is a potent and non-selective P-glycoprotein (P-gp) inhibitor with an EC50 of 0.69 µM. MC70 is an ABC transporters inhibitor and anticancer agent. MC70 interacts with ABCB1, ABCG2 and ABCC1 .
loading...
    loading...
Cat. No.: HY-50879R
CAS No.: 143664-11-3
Synonyms: GF120918 (Standard); GW0918 (Standard); GG918 (Standard); GW120918 (Standard)
Research Areas:  

Cancer

Elacridar (Standard) is the analytical standard of Elacridar. This product is intended for research and analytical applications. Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer .
loading...
    loading...
Cat. No.: HY-128038
CAS No.: 66164-07-6
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

N-Desmethyl-loperamide is a major metabolite of loperamide, a drug that selectively activates peripheral μopioid receptors with a Ki value of 0.16 nM. N-Desmethyl-loperamide is a substrate of the ATP-dependent efflux transporter P-glycoprotein .
loading...
    loading...
Cat. No.: HY-155152
CAS No.: 3052839-42-3
Target:  

P-glycoprotein BCRP

Research Areas:  

Cancer

P-gp/BCRP-IN-2 (compound 15) is an oxadiazole derivative and a dual inhibitor of the ABC transporter P-glycoprotein (IC50: 1.6 nM) and BCRP (IC50: 600 nM). P-gp/BCRP-IN-2 also enhances the anti-proliferative effects of Doxorubicin (HY-15142A) in drug-resistant human adenocarcinoma colon cancer cell lines HT29/DX and MDCK-MDR1 cells .
loading...
    loading...
Cat. No.: HY-W777317
CAS No.: 1189481-51-3
Elacridar-d4(Major) is the deuterium labeled Elacridar (HY-50879). Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer .
loading...
    loading...
Cat. No.: HY-50880R
CAS No.: 143851-98-3
Synonyms: GF120918A (Standard)
Research Areas:  

Cancer

Elacridar (hydrochloride) (Standard) is the analytical standard of Elacridar (hydrochloride). This product is intended for research and analytical applications. Elacridar hydrochloride (GF120918A) is an orally active P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar hydrochloride can be used to examine the influence of efflux transporters on agent distribution to brain and it can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-149981
CAS No.: 3041121-57-4
Target:  

P-glycoprotein

Research Areas:  

Cancer

P-gp inhibitor 13 is a P-gp inhibitor. P-gp inhibitor 13 can reverse P-glycoprotein-mediated paclitaxel resistance in A2780/T cell. P-gp inhibitor 13 can be used for the research of advanced acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-10289
CAS No.: 813452-18-5
Synonyms: RO-4876904
Carmegliptin (RO-4876904) is an orally active and potent DPP IV inhibitor with a human DPP IV IC50 of 6.8 nM. Carmegliptin binds to the S1 pocket of DPP IV, blocks the degradation of GLP 1, potentiates endogenous GLP 1, increases plasma insulin levels, alleviates hyperglycemia, improves glucose tolerance. Carmegliptin acts as a substrate for human P glycoprotein without inhibiting the transporter, shows low in vitro cell permeability. Carmegliptin can be used for the research of type 2 diabetes, non insulin dependent diabetes mellitus .
loading...
    loading...
Cat. No.: HY-10289A
CAS No.: 813452-14-1
Synonyms: RO-4876904 hydrochloride
Carmegliptin hydrochloride (RO-4876904 hydrochloride) is an orally active and potent DPP‑IV inhibitor with a human DPP‑IV IC50 of 6.8 nM. Carmegliptin hydrochloride binds to the S1 pocket of DPP‑IV, blocks the degradation of GLP‑1, potentiates endogenous GLP‑1, increases plasma insulin levels, alleviates hyperglycemia, improves glucose tolerance. Carmegliptin hydrochloride acts as a substrate for human P‑glycoprotein without inhibiting the transporter, shows low in vitro cell permeability. Carmegliptin hydrochloride can be used for the research of type 2 diabetes, non‑insulin‑dependent diabetes mellitus .
loading...
    loading...
Cat. No.: HY-13774
CAS No.: 908859-10-9
Target:  

P-glycoprotein BCRP

Research Areas:  

Cancer

WK-X-34 is a low-toxicity, highly effective multidrug resistance reversal agent. By potently inhibiting the transport functions of P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP), WK-X-34 significantly increases the intracellular accumulation of anticancer drugs and radiotracers in drug-resistant cells. WK-X-34 exerts no significant effect on MRP transporters. WK-X-34 not only restores the chemosensitivity of multidrug-resistant ovarian cancer cells, but also significantly enhances the uptake of 99mTc-Sestamibi in P-gp-positive xenograft tumors, brain and intestinal tissues. WK-X-34 exhibits extremely low toxicity and favorable safety profiles both in vitro and in mice (at doses up to 50 mg/kg), and can be used for research on overcoming multidrug resistance in ovarian cancer .
loading...
    loading...
  • 1